Nutriband Inc. (NASDAQ:NTRB) Short Interest Down 24.4% in January

Nutriband Inc. (NASDAQ:NTRB - Get Free Report) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 54,900 shares, a decline of 24.4% from the December 31st total of 72,600 shares. Based on an average daily volume of 153,100 shares, the short-interest ratio is presently 0.4 days. Approximately 1.1% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Noble Financial initiated coverage on shares of Nutriband in a report on Wednesday, January 22nd. They set an "outperform" rating and a $13.00 target price for the company.

Nutriband Trading Down 11.2 %

NASDAQ NTRB traded down $0.93 on Monday, hitting $7.36. 86,577 shares of the company were exchanged, compared to its average volume of 442,269. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.96 and a quick ratio of 4.83. Nutriband has a twelve month low of $2.22 and a twelve month high of $11.78. The firm has a market capitalization of $81.77 million, a P/E ratio of -10.37 and a beta of 1.08. The company's 50 day moving average price is $4.96 and its 200-day moving average price is $5.50.

Nutriband (NASDAQ:NTRB - Get Free Report) last released its quarterly earnings results on Tuesday, December 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter. Nutriband had a negative net margin of 338.51% and a negative return on equity of 54.49%. Analysts predict that Nutriband will post -0.6 earnings per share for the current fiscal year.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.